GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

rosnilimab   Click here for help

GtoPdb Ligand ID: 14271

Synonyms: ANB-030 | ANB030
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rosnilimab (ANB-030; AnaptysBio) is a programmed cell death 1 (PD-1) monoclonal antibody that activates the PD-1 signaling pathway as a mechanism to suppress pathogenic T cell-mediated immune activation for the treatment of autoimmune disorders [1,3-4]. PD-1 agonist monoclonals are claimed in AnaptysBio patent US20220235132 [2]. Peptide sequences for 3.7C6 (APE12095) clones in this patent match the complementarity-determining region (CDR) sequences that form the antigen-binding site of rosnilimab, as annotated by IMGT.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Afshari A, Khorramdelazad H, Abbasifard M. (2025)
Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission.
Int Immunopharmacol, 162: 115162. [PMID:40617046]
2. Kehry M, Parmley S, Morse RP, Gold GN, Fisher J, Dahl ME, Marino MH, Kalapanda R. (2022)
Pd-1 agonist and method of using same.
Patent number: US20220235132A1. Assignee: Anaptysbio Inc. Priority date: 04/06/2020. Publication date: 28/07/2022.
3. Luu K, Dahl M, Hare E, Sibley C. (2024)
DOP81 Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trial.
Journal of Crohn s and Colitis, 18 (Supplement_1): i226. DOI: 10.1093/ecco-jcc/jjad212.0121
4. Ramírez-Marín HA, Tosti A. (2022)
Emerging drugs for the treatment of alopecia areata.
Expert Opin Emerg Drugs, 27 (4): 379-387. [PMID:36408593]